Evaluation of the clinical utility of medical tests in chronic urticaria Authors: Jorge Sánchez, Ana-Lorena Caraballo, Elizabeth García Published: 2026 ABSTRACT Graphical abstractKey words: Accuracy, clinical utility, chronic spontaneous urticaria, diagnosis, prognosis, urticaria, laboratory tests, sensitivity, specificity Chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU) are diseases with a high clinical and economic impact on patients and health systems,1,2 where patients and doctors often have multiple concerns regarding the management (eg, What causes the disease?), and prognosis (eg, Will the treatment work?). Medical tests—including laboratory assays, imaging studies, questionnaires, and challenge procedures—are intended to support diagnosis, characterize endotypes, detect comorbidities, monitor diseases, or predict outcomes related with health.3 Despite clinical guidelines recommending only a few tests, around the world multiple tests are performed for the study of urticaria in clinical practice according to observational studies.1,2,4,5 Additionally, the accuracy (eg, concordance, sensibility, specificity) is often unknown even for those tests recommended in clinical guidelines.5 Diagnostic accuracy and predictive accuracy, refers to the ability of a test to truly discriminate between 2 or more clinical states either in the present (diagnosis) or in the future (prognosis).6,7 For example, having or not having urticaria, or identifying patients who will or will not respond to antihistamines. Measures such as sensitivity, specificity, predictive values, and likelihood ratios quantify this capacity. On the other hand, clinical utility is defined as the ability of a test, treatment, or medical technology to provide information or actions that result in improved health outcomes for the patient.8, 9, 10 It measures the value and actual effectiveness of an intervention in clinical practice, going beyond accuracy by assessing how the outcome guides therapeutic decisions (decision-making).8, 9, 10 One of the principles of precision medicine is to provide timely management according to the specific needs of each patient.11,12 Therefore, having medical tests with high accuracy, would help to reduce urticaria misdiagnosis, as well as select the best therapy for each patient, and identify the main endophenotypes early, improving the prediction of clinical evolution and the possible presence of comorbidities. Therefore, this study’s objective was to evaluate the operational accuracy and the clinical utility of medical tests frequently used in chronic urticaria, seeking to establish their value in clinical practice, and to explore emerging diagnostic approaches with potential relevance for future clinical practice. Methods Study design For the aim of the study, we divided the evaluation into 3 sequential phases (Fig 1). First, we identified medical tests used or potentially used in urticaria (CSU or CIndU) clinical practice through a review of the literature and consultation to urticaria specialists around the world from the World Allergy Organization (WAO) excellence centers (https://worldallergy.org/membership) and from the Urticaria Centers of Reference and Excellence (UCARE) (https://ucare-network.com/) network, to identify the most frequently used medical tests and the reason for their indication. Second, the operational accuracy was evaluated with population from the URTICA (Urticaria Research of Tropical Impact Control Assessment) cohort and the ACUTE (Acute to Chronic Urticaria Time Evolution) cohort, according with the STARD (Standards for Reporting of Diagnostic Accuracy) initiative using different measures according with the evaluation design and the clinical outcome. Third, in those tests with high operational accuracy, the clinical utility was evaluated based on their impact on management decisions and patient outcomes. In this study, we did not included evaluation of internet bot and predictive indices. Study design. The study has 3 phases: (1) identification of medical tests in urticaria; (2) evaluation of the diagnostic or prediction accuracy; (3) evaluation of clinical utility. LR + (LR−), Likelihood ratio positive (negative), VPN, negative predictive value; VPP, positive predictive value. Identification of medical tests in urticaria We conducted a literature review from January 1, 1990 to June 30, 2025, with the following operational aim: “diagnostic and/or predictive tests for urticaria.” Additionally, we did a survey among 20 allergists and 10 dermatologists from UCARE centers and WAO excellence centers located in Europe, Asia, and America and from other physicians in their region (n = 28), to gather their perspectives. From the search and the survey, we identified 4 aspects: (1) the outcome(s) for which the test is requested, (2) the patient for whom it is indicated, (3) the time (beginning, follow-up) at which it is requested, and (4) the frequency of indication in the patient. Some tests that are not widely available but, according to the literature, could be clinically useful were also included. Evaluation of medical tests accuracy The accuracy of each test was assessed using conventional parameters such as sensitivity, specificity, and positive and negative predictive values. A single test could have multiple clinical outcomes of interest, different gold standards. Below we describe the study population, the reference parameters used, and the clinical outcomes of interest. Study population For each clinical outcome, we used an appropriate population. Medical tests were evaluated in groups of patients over 18 years of age from the URTICA and ACUTE cohorts. Briefly, the URTICA and ACUTE cohorts included patients with urticaria from any age. URTICA started in 2016 and included urticaria patients with CSU or CIndU from 3 primary care centers and 3 urticaria specialist centers, in 2 cities from Colombia. The main objective of the URTICA cohort is to evaluate risk factors associated with different outcomes in urticaria. The ACUTE cohort includes patients with acute urticaria and follow-up independent of their evolution (remission, chronic urticaria). In the present study, we included those patients that progressed to chronic urticaria. Both cohorts maintain continuous recruitment and monitoring of patients even after urticaria remission.4,13, 14, 15, 16 Some tests are routinely ordered in the study population in the first clinical appointment (complete blood count, IgG anti-thyroid peroxidase [TPO], total IgE, acute phase reactants). Other tests were indicated routinely but only in patients with specific conditions or clinical characteristics (eg, non-steroidal anti-inflammatory drugs [NSAIDs] challenge tests [CTs], inducible CTs, food CTs, skin prick test [SPT], specific IgE [sIgE]). The tests that are not routinely requested in the study centers were prospectively done in a group of patients for the present study. For these tests, patients in the cohort were randomly selected for each accuracy evaluation; in this way the risk of selection bias was reduced (Table I). For treatment prognostic accuracy, only tests obtained prior to treatment initiation were included to prevent treatment-induced misclassification. Table IClinical and sociodemographic characteristics of URTICA and ACUTE cohortsSociodemographic characteristicsURTICA/ACUTE cohort (N = 1,318)Age (y)31 ± 11.3Female1013 (76.7)Comorbidities Asthma132 (10) Atopy421 (31.9) Anaphylaxis124 (9.4) Hypothyroidism185 (14) NSAID hypersensitivity211 (16) Chronic inducible urticaria399 (30.2) Other autoimmune diseases60 (4.5) Other comorbidities321 (24.3)CSU clinical characteristics Urticaria time (mo)32 ± 18 Angioedema548 (41.5) UAS728 ± 8 UCT [median, (SD)]11 ± 7Laboratory tests Eosinophils in blood128 ± 151 (range 1028) Basophils in blood89 ± 61 (range 102) IgG anti-TPO8.8 ± 30.6 (range 262) CRP0.2 ± 1.7 (range 11.1)All patients were over 18 years.Values are mean ± SD or n (%) unless otherwise indicated.UAS7, Urticaria activity score, 7 days; UCT, Urticaria control test. Clinical and sociodemographic characteristics of URTICA and ACUTE cohorts All patients were over 18 years. Values are mean ± SD or n (%) unless otherwise indicated. UAS7, Urticaria activity score, 7 days; UCT, Urticaria control test. Outcomes We evaluated the accuracy of medical tests for 5 predefined outcomes: (1) diagnostic support for chronic urticaria (CSU or CIndU); (2) evaluation of autoimmune endotypes; (3) presence of comorbidities or differential diagnosis; (4) potential urticaria triggers; and (5) predicting clinical response to therapy. For each outcome, an appropriate reference standard (gold standard) was defined based on international guidelines and expert consensus. For evaluation of autoimmune endotypes, basophil activation tests (BATs) were used as reference parameter.17 For urticaria diagnosis and comorbidities, physical examination by urticaria specialist and validated diagnosis criteria of each disease were used, for example, the objective demonstration of wheals (hives) or angioedema.5 For urticaria triggers, CTs were performed,18, 19, 20, 21 and for clinical response, the urticaria control test was used.5 Protocol of BAT, inducible CT, food CT, NSAID CT, and other tests are presented in this article’s Online Repository (available at www.jaci-global.org). Evaluation of clinical utility Clinical utility was assessed in the tests with demonstrated accuracy. For operational purposes, a test was defined as “clinically useful” if performing it improved medical management for the outcome versus not performing the test8, 9, 10; if its result changed diagnostic classification, treatment decision, or restriction policy; and that change plausibly improved patient outcomes or avoided unnecessary interventions. We asked urticaria specialists (n = 20) about the clinical utility of each test according to each clinical outcome. Ethical considerations This study was approved by the ethics committee of the University of Antioquia and the Alma Mater de Antioquia Hospital (Code: BE-IIM 200910). Written informed consent was obtained from all participants in both the URTICA cohort (IN40-2016) and the ACUTE cohort (IN4-2022). Sample size Nonprobability convenience sampling was carried out among the URTICA and ACUTE cohorts and according to the order of arrival at clinical centers. The sample calculation was done according to the criterion of “events by variable”22, 23, 24; this criterion is based on obtaining several outcomes for each variable studied. We decided to include a minimum of 30 subjects for each variable according with the frequency expected of the outcomes.15 Following: n = 30 × k/i where k is the number of variables and i is the incidence of the outcome of interest: n= 30 × 16/0.5 = 960. Expecting a loss of 10% (96 patients), the minimal sample size would be 1056 patients. Statistical analysis Total number and proportions were reported for categorical data. The mean ±SD were reported for continuous variables after evaluation of the data distribution by Shapiro-Wilk test. In tests where there is no comparison group, accuracy was assessed according to the concordance of the result with the CT. For the assessment of diagnostic accuracy, priority was given to reporting effect size estimates over the P value, because the latter does not reflect clinical utility or the uncertainty of the estimate. Following international recommendations, the test's performance was expressed using sensitivity, specificity, and other precision parameters, strictly accompanied by their respective 95% CIs. This approach allows us to determine not only the tool's discriminatory capacity against the gold standard, but also the accuracy of the results obtained and their applicability in evidence-based medical decision-making. Analyses were performed using SPSS Statistics program, version 26 (IBM Corp, New York, NY), GraphPad Prism software, version 10 (Dotmatics, San Diego, Calif) and Jamovi, version 2.3 (Jamovi, Sidney, Australia). Results Medical tests identified A total of 26 medical tests were identified through literature review and expert consultation (Table II). Of these, 16 were formally evaluated for diagnostic or predictive accuracy in the URTICA and ACUTE cohorts: (1) erythrocyte sedimentation rate (ESR), (2) C-reactive protein (CRP), (3) total IgE (tIgE), (4) SPT, (5) sIgE, (6) IgG anti-TPO, (7) IgG anti-thyroglobulin, (8) IgE anti-TPO, (9) blood basophils, (10) blood eosinophils, (11) vitamin D, (12) antinuclear antibodies (ANAs), (13) extractable nuclear antigens (ENAs), (14) autologous serum skin test (ASST), (15) NSAID-hypersensitivity self-report, and (16) photograph. We also evaluated trigger restrictions recommended in patients based in self-reports for inducible triggers and NSAID. The remaining tests were excluded due to limited availability, insufficient sample size, or technical constraints. Table IIIdentified variables and population selection according to outcomeMedical testsOutcomeFrequency mean (min to max), %Included in the studyPhotographCSU diagnosis and differential diagnosis20 (0-100)Yes. Evaluation in patients with chronic urticaria.ESRDifferential diagnosis81 (32-100)Yes. Evaluation in patients with CSU.CRPDifferential diagnosis93 (40-100)Yes. Evaluation in patients with CSU.Total IgEEndotypes94 (63-100)Yes. Evaluation in patients with CSU.IgG anti-TPOEndotypesComorbidities91 (38-100)Yes. Evaluation in patients with CSU.IgG anti-TgEndotypesComorbidities61 (38-88)Yes. Evaluation in patients with CSU.IgE anti-TPOEndotypes1 (0-3)Yes. Evaluation in patients with CSU.Food-IgE sensitizationIdentification of CSU triggers31 (0-80)Yes. Evaluation in patients with CSU and food trigger self-report.Contact-IgE sensitizationIdentification of CSU triggers17 (0-25)Yes. Evaluation in patients with CSU and contact trigger self-report.BasophilsEndotypesDifferential diagnosis86 (76-100)Yes. Evaluation in patients with CSU.EosinophilEndotypesDifferential diagnosis55 (0-100)Yes. Evaluation in patients with CSUVitamin DTherapeutic response11 (0-31)Yes. Evaluation in patients with CSU.∗ANAEndotypeDifferential diagnosis22 (0-100)Yes. Evaluation in patients with CSU.∗ENAEndotypeDifferential diagnosis15 (0-100)Yes. Evaluation in patients with CSU.∗ASSTEndotype18 (0-100)Yes. Evaluation in patients with CSU.∗NSAID hypersensitivity self-reportIdentification of CSU triggers18 (0-100)Yes. Evaluation in patients with CSU and NSAID trigger self-report.ASPTEndotype15 (0-100)No. High concordance with ASST.BilirubinDifferential diagnosis15 (0100)No. Insufficient sample size and possible selection bias.CreatinineDifferential diagnosis30 (0-100)No. Insufficient sample size and possible selection bias.ASTDifferential diagnosis15 (0-100)No. Insufficient sample size and possible selection bias.ALTDifferential diagnosis15 (0-100)No. Insufficient sample size and possible selection bias.Complement 4 (C4)Differential diagnosis24 (0-100)No. Insufficient sample size and possible selection bias.IgE anti-IL24, TF, EPX, ECPCSU diagnosis and endotype1 (0-2)No. Technical limitations and/or insufficient sample size.IgG anti-IgE, FcεRI, FcεRIIEndotype1 (0-2)No. Technical limitations and/or insufficient sample size.TSHDifferential diagnosis43 (21-100)TSH was used as reference parameter for hypothyroidism.HIVDifferential diagnosis15 (0-100)NoThe frequency of ordering patients for each test was estimated according to the survey among WAO excellence centers and UCARE networks.ALT, Aspartate aminotransferase; APST, autologous skin plasma test; AST, aspartate alanine transferase; ECP, eosinophil cationic protein; max, maximum; min, minimum; TF, Tissular factor; Tg, thyroglobulin; TSH, thyroid-stimulating hormone.∗These tests were evaluated in a subgroup of patients because it was not rutinary done in the health centers participating in the investigation. Identified variables and population selection according to outcome The frequency of ordering patients for each test was estimated according to the survey among WAO excellence centers and UCARE networks. ALT, Aspartate aminotransferase; APST, autologous skin plasma test; AST, aspartate alanine transferase; ECP, eosinophil cationic protein; max, maximum; min, minimum; TF, Tissular factor; Tg, thyroglobulin; TSH, thyroid-stimulating hormone. These tests were evaluated in a subgroup of patients because it was not rutinary done in the health centers participating in the investigation. Tests to support the diagnosis of urticaria The presence of hives or angioedema is essential for urticaria diagnosis. Among 1134 patients initially diagnosed with chronic urticaria based solely on clinical description in the first clinical appointment, concordance with subsequent photographic confirmation was 71.8% (n = 814) (Fig 2). Therefore, 28.2% (n = 320) were reclassified after objective documentation, indicating an initial misdiagnosis. Due to the lack of a comparator group, we were unable to assess sensitivity and specificity. Misdiagnosis was more common among primary care physicians (n = 272 of 821, 33.1%) than urticaria specialists (n = 48 of 313, 15.3%). Medical test for urticaria diagnosis. Presence of hives or angioedema was evaluated in patients with a clinical diagnosis by urticaria specialist. Tests to identify endotypes in urticaria Different tests have been proposed for autoimmune endotype diagnosis (tIgE, IgG anti-TPO, IgE anti-TPO, ASST, ANAs, ENAs, basophil, eosinophil) (Table III). We evaluated some of these tests using as reference parameter BAT in 60 patients with CSU. Using the combined parameter of IgG anti-TPO high and tIgE low (aTPOhigh/IgElow). A total of 15 patients had a positive BAT; 2 of them had aTPOhigh/IgElow and IgE anti-TPO, 4 only aTPOhigh/IgElow, and 9 only IgE anti-TPO. The operating performance had a low sensitivity (40%) and a high specificity (93%) may be because of the low frequency of aTPOhigh/IgElow subjects. IgE anti-TPO had a sensitivity of 73% and specificity of 91%. Table IIIMedical tests for autoimmune endotypesSensitivity (95% CI), %Specificity (95% CI), %PPV (95% CI), %NPV (95% CI), %LR+ (95% CI)LR− (95% CI)aTPOhigh/IgElow40 (16-67)93 (8198)67 (36-87)82 (75-87)5.71 (1.7-21)0.65 (0.42-0.98)IgE anti-TPO73 (44-92)91 (79-97)73 (50-88)91 (81-96)8.1 (3.1-22)0.3 (0.13-0.68)ASST73 (44-92)62 (46- 76)39 (28-51)88 (74-94)1.92 (1.2-3)0.23 (0.18-1)BAT was used as reference parameter.NPV, Negative predictive value; PPV, positive predictive value. Medical tests for autoimmune endotypes BAT was used as reference parameter. NPV, Negative predictive value; PPV, positive predictive value. For ASST, the sensitivity to identify autoreactivity was 73%, specificity 62%, and positive predictive value 38%. Basopenia, eosinopenia, ANAs, and ENAs have been associated with type 2b autoimmunity and some urticaria specialists suggest that sIgE could be used as a biomarker of type 1 autoimmunity; however, because BAT evaluation was carried out using whole blood, it was not possible to evaluate these specific mechanisms. Tests to evaluate comorbidities in urticaria According to international guidelines, ESR and/or CRP have been suggested as routinary exams for CSU. The most common indication for these tests according to the urticaria specialists consulted was evaluation of other inflammatory diseases. As a parameter of reference, we evaluated the presence of different diseases associated with hives or angioedema (vasculitis, cancer, any autoimmune diseases, other chronic inflammatory diseases) (Table IV). The sensitivity of these tests was moderate, and the specificity was high. From the 81 patients with urticaria and a chronic inflammatory disease, the diagnosis was already known in 74 prior to testing; therefore, the tests routinely used in CSU only identified 7 patients (8.6%) with new diagnosis. We did a subanalysis according to different groups of chronic diseases with little change in the diagnostic accuracy (Fig 3). Table IVMedical tests for comorbiditiesSensitivity (95% CI), %Specificity (95% CI), %PPV (95% CI), %NPV/(95% CI), %LR+ (95% CI)LR− (95% CI)ESR/CRP51 (39-61)96 (93-97)66 (54-75)93 (90-93)12.7 (7.8-20)0.51 (0.41-0.64)IgG anti-TPO89 (78-97)99 (97-99)92 (82-96)99 (97-99)95 (39-229)0.11 (0.06-0.30)IgG anti-Tg78 (65-87)99 (97-99)91 (80-95)97 (95-98)83 (34-201)0.22 (0.14-0.36)Diagnosis criteria for different diseases were used as reference parameters. Medical tests for comorbidities Diagnosis criteria for different diseases were used as reference parameters. Medical tests for comorbidities. For NSAID-exacerbated cutaneous disease (NECD), NSAID CT was used as reference parameter (A). For evaluation of food sensitization, oral food challenge was used as reference parameter and for contact urticaria contact CTs (B). For the diagnosis of hypothyroidism, IgG anti-TPO and IgG anti-thyroglobulin presented a high diagnostic accuracy. IgG anti-TPO had the greater sensitivity; performing both tests only increased the sensitivity by 2%. However, most cases (52 of 63) were previously diagnosed, and testing newly identified only 7 cases (17.4%). Tests to evaluate triggers in urticaria Food SPT/sIgE had a concordance >98%, so we present them together. From 276 patients with CSU reporting suspected food triggers, only 4 (1.4%) had a positive oral food challenge. SPT/sIgE tests demonstrated a high sensitivity and specificity using oral food challenge as the reference parameter. Other allergens evaluated with SPT/sIgE had a concordance >92%, so we present them together. From the database, we identified 136 patients reporting suspicion of ≥1 contact-trigger (eg, detergents, lotions, animals): 68 with an allergenic source (cats 20, dogs 16, plants 30) and from them 10 patients had a positive contact CT and 6 were detected with the SPT/sIgE (sensitivity 60%, specificity 88%). During the evaluation period, 104 patients with self-report of NSAID hypersensitivity were to take to NSAID CT. The concordance of self-report and NSAID CT was 31.7% for NSAID-exacerbated cutaneous diseases diagnosis. Furthermore, in the cohort 96 patients with clinical history of CSU and a positive NSAID CT underwent a second CT after CSU remission; 72 (75%) had also remission of NSAID-exacerbated cutaneous diseases. Tests to predict therapeutic response in urticaria Different tests have been proposed with this aim (basophil, eosinophil, ASST, vitamin D, ANA, ENA) (Table V). Because the low frequency of positivity, we evaluated ANAs and ENAs, together. None of the tests had a sensitivity or positive or negative predictive value >50% for predicting antihistamine response. Table VPredictors of therapy responseClinical response toMedical tests (n)Sensitivity (95% CI), %Specificity (95% CI), %VPP (95% CI), %VPN (95% CI), %LR+ (95% CI)LR− (95% CI)AntihistaminesBasopenia (336)16 (10-21)67 (58-74)41 (31-50)35 (32-38)0.48 (0.32-0.71)1.25 (1.1-1.4)Eosinopenia (336)10 (6-15)78 (70-84)40 (28-52)37 (35-39)0.45 (1.1-1.2)1.15 (1.04-1.2)Vitamin D (90)44 (29- 60)44 (29-60)44 (34-54)44 (34-54)0.79 (0.5-1.2)1.27 (0.8-1.9)ANAs/ENAs (90)16 (4-36)68 (46-85)33 (14-59)45 (37-52)0.5 (0.1-1.4)1.24 (0.9-1.7)ASST (65)34 (19-52)47 (28-65)43 (29-56)38 (27-48)0.64 (0.3-1.1)1.4 (0.9-2.2)OmalizumabBasopenia (48)8 (1-20)44 (13-78)38 (14-67)10 (5-18)0.14 (0.04-0.4)2.09 (0.9-4.3)Eosinopenia (48)8 (1.6-20)33 (7-70)33 (13-61)8 (3-17)0.12 (0.04-0.3)2.79 (1.09-7)BAT was used as reference parameter. Basopenia was defined as <10 cells/μL, and eosinopenia was defined as <50 cells/μL. Predictors of therapy response BAT was used as reference parameter. Basopenia was defined as <10 cells/μL, and eosinopenia was defined as <50 cells/μL. From the 137 patients without clinical response to antihistamines, 48 received omalizumab and 39 had clinical control after 4 months. For the sample size we could not evaluate prediction accuracy of vitamin D, ANA, ENA, or ASST for omalizumab response; among the 90 patients included for evaluation of these biomarkers, only 7 received omalizumab during the study period. Clinical utility of tests is presented in Fig 4. Medical tests for comorbidities. Summary of clinical utility of different tests according to 4 outcomes: (1) urticaria diagnosis, (2) triggers, (3) endotypes, and (4) comorbidities. Discussion Medical tests are tools commonly used in the clinical evaluation that expand the capacity for perception for the diagnosis or prognosis of a disease.25, 26, 27 In the 2009 update of urticaria guideline,28 many tests were discouraged because they appeared to have little clinical utility. Tarbox et al28 reported that of 1872 tests performed on 166 urticaria patients, only 17% were positive, and in <1% of cases, they altered medical management. In the 2022 GA2LEN guidelines,5 fewer tests in the initial evaluation of urticaria were recommended, but the clinical benefit of ordering some of these tests was not explained in detail in the guideline. Additionally, with the appearance of new therapies, new potential biomarkers have emerged specially for evaluation of pharmacotherapy response and identification of endotypes, but more of these biomarkers have been not evaluated for clinical utility. How much a test contributes to clinical practice is defined by its clinical utility. Clinical utility is not just about whether a test works (accuracy), but whether its result leads to effective action that improves the patient's life through treatment, prevention, or management.10 In the management of urticaria, the direct cost of tests represented ∼1% of the total expenditure4; however, performing these tests are accompanied by a significant time commitment of the patient (between 3 and 6 days per year) and it is not clear how the performance of these tests influenced the decision-making of the physicians. According to our results, we observed that the request for tests in urticaria is highly frequent. This may be due to several factors, such as individual physician's beliefs, local guidelines, improving the patient's perception that something is being done for their illness, among other reasons. However, reviewing the literature, we observed that, although many of these tests are supported by studies showing a statistical difference, virtually none of these studies evaluate their operational performance or clinical utility. Statistical associations allow us to understand possible patterns in biological processes and to establish potential clinical targets that are not always relevant in clinical practice. For example, Kolkhir et al29 described a statistical association where patients with CSU who have low levels of tIgE and positive anti-TPO IgG were more likely to have type 2b autoimmunity. However, using the same database, Sanchez et al30 observed that the diagnostic performance of these tests had a low sensitivity (30%), which means, in practical terms, that of 10 patients with type 2b autoimmunity, only 3 could be detected with the test, calling into question its clinical utility. Therefore, recommendations regarding which tests to perform in patients with urticaria should be limited to those with good operational performance for specific outcomes. According to our results, tests recommended for 2022 GA2LEN urticaria (IgG anti-TPO, hemogram, acute phase reactant, and tIgE),5 could be useful for endotyping (aTPOhigh/IgElow) and for comorbidities evaluation (acute phase reactant, IgG anti-TPO), but their clinical utility was conditional, indicating a potential use, but in specific situations, indicating that it may not be necessary to perform it on all patients. We observed that some tests, such as food IgE sensitization, IgG anti-TPO, IgE anti-TPO, and CTs (physical stimuli or NSAID), could be useful. The predictive values of these tests may vary in each region according to the outcomes (eg, food trigger, NSAID trigger); however, the diagnostic performance according to sensitivity and specificity indicates that these are tests with acceptable accuracy and potential clinical utility to avoid unnecessary restrictions and to identify comorbidities or endotypes. It is important to emphasize that these tests have been proposed for different outcomes so they are not always clinically useful. For example, even though IgE sensitization could be useful to identify contact triggers, it has also been associated with a greater number of comorbidities related to type 2 inflammation; therefore, it is not appropriate to recommend these tests as routine assessments for urticaria, but rather as a separate study in patients with specific conditions. We found that photographic documentation and CTs demonstrated the most tangible clinical benefit. Diagnostic misclassification approaching 30% in initial clinical evaluation underscores the importance of objective confirmation. Similarly, NSAID CTs prevented unnecessary long-term drug avoidance and demonstrated reversibility after CSU remission, illustrating dynamic disease mechanisms. On the other hand, other tests that are commonly requested in various regions showed low diagnostic performance, limiting their clinical utility. Acute phase reactants (CRP and ESR) had high specificity but low sensitivity, making it necessary to reconsider the current recommendation to perform them in all patients with CSU and instead consider them only in those with additional clinical symptoms that could suggest a systemic inflammatory process other than urticaria. The presence of eosinopenia, basopenia, vitamin D levels, ANAs, and ENAs have been reported in various studies with a statistical association for several clinical outcomes, but the clinical utility of these tests was limited due to their low accuracy regarding these outcomes of interest. The evaluation of each test should be done holistically; the ASST test had moderate performance in both sensitivity and specificity, however its discriminatory capacity was low in identifying the autoimmune endotype, so it has no clinical utility. Additionally, the limited predictive performance of biomarkers for antihistamine response reflects a broader issue in urticaria research: When individual biomarkers with sufficient predictive capacity are not available, it becomes necessary to build prognostic calculators that combine several variables and allow for better accuracy.24,31,32 An important strength of this study is the integration of diagnostic accuracy metrics with an explicit evaluation of clinical utility. Few studies in urticaria extend beyond reporting sensitivity and specificity to address whether testing changes management. The large number of patients and their collection from primary care centers and specialists aid in reducing selection bias. Additionally, follow-up over time, as well as the administration of multiple tests to all participants, help reducing measurement bias. One strength of the study is that the BAT assessment was performed by direct measurement of IgE autoantibodies after depletion of IgG autoantibodies in the serum, which reduces interference and makes a specific evaluation of type 1 autoimmunity. Limitations of this study include sample size constraints for some subgroup analyses and potential variability in prevalence affecting predictive values. However, likelihood ratios remain relatively stable across populations, enhancing generalizability. We attempted to evaluate as many tests as possible; however, the sample size and technical limitations for some procedures prevented us from including all identified tests. Transforming variables (eg, using a different cutoff point, combining variables, or using continuous sampling) could improve accuracy; however, implementing these procedures would require a larger sample size. Therefore, we decided to evaluate the tests as reported in the literature and/or by urticaria specialists. Additionally, defining the point according to local reference values would limit its usefulness at a global level. About BAT for IgE autoantibody evaluation, tests performed in research laboratories must be validated for subsequent open use in clinical practice. Therefore, this test cannot yet be considered universally applicable in clinical practice. An upcoming project of the UCARE network (VANGUARD project; VAlidation of Biomarkers, in NeGative and Positive Chronic Spontaneus Urticaria) will allow the replicability of this test to be evaluated in different centers, bringing the possibility of its use in clinical practice closer. We were unable to evaluate the clinical accuracy of all potential biomarkers associated with the response to omalizumab with a homogeneous sample; therefore, we could not determine the clinical utility of some of them. Although the photo evaluation did not have a parallel comparator group, we performed a before-and-after evaluation that supports the recommendations made and highlights their clinical utility; however, future evaluations with a comparator group are necessary to confirm the results. In conclusion, while several tests are commonly and traditionally used in the study of patients with urticaria, few have good operational performance, which limits their clinical utility. Furthermore, for many clinical outcomes of interest we were unable to identify predictive or diagnostic evaluations; therefore, the challenge for the near future is not only to continue to advance in pathogenesis and immunologic mechanisms or to discover more associations, but to develop clinically actionable tools that meaningfully guide management, improve patient-centered outcomes, and optimize health care resources. Disclosure statement This study was funded by the initiative Global Research on Environment, Allergy, and Autoimmunity in the Tropics (GREAT) that received donations with unrestricted use from public (University of Antioquia, MinCiencias) and private (Novartis, Sanofi, Glaxon, AstraZeneca) entities and was administrated by the Colombian Association of Allergy, Asthma, and Immunology (ACAAI by its Spanish acronym). Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.